News for hackers. Stuff that matters.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by rayiner on Wednesday May 24, 2017 @10:14PM (#14414878)
I have my concerns about drug advertising, but pharma company SG&A isn't out of line with say tech company SG&A: For 2014-2015, the ratio between R&D spending and SG&A spending is 0.59 at Pfizer, 0.75 at Google, 0.56 at AstraZeneca, 0.43 at Apple, and 0.58 at Microsoft.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by Fomite on Thursday May 25, 2017 @12:08AM (#14415243)
Though in fairness, Apple isn't trying to get you to ask a licensed professional who has years of education about the new Apple Watch.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by spullara on Thursday May 25, 2017 @03:08AM (#14415791)
They might once it does glucose measurements... And I hope they do.